Biotech Startups

A nutrition technology company that uses wild-type unicellular aquatic organisms to produce protein- and fiber-rich, non-GMO ingredients (marketed as Marine Whey) for food applications. It partners with global food corporations to deliver affordable nutrition, with a focus on the Global South.

4 investors

Nutromics is developing a wearable patch for continuous, real-time monitoring of biomarkers in hospital settings, starting with therapeutic drug monitoring of the antibiotic vancomycin. The technology aims to help clinicians keep patients within the therapeutic range and is intended to expand into infectious disease, cardiology, and renal indications.

4 investors

Nuvation Bio is a global oncology company that develops novel cancer therapies through its own drug discovery programs and business development, serving cancer patients. Founded in 2018, it became a commercial-stage company in 2025.

4 investors

NX Prenatal is a molecular diagnostics company developing exosome-based liquid biopsy assays that detect adverse pregnancy conditions such as preterm birth, preeclampsia, and placenta accreta. Its non-invasive tests help physicians identify at-risk pregnancies to intervene and reduce complications for mother and child.

4 investors

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.

4 investors

Octagon Therapeutics is a biotech company developing new medicines for autoimmune diseases with unmet clinical need, based on scientific research from Harvard. It serves patients living with autoimmunity through its drug development programs.

4 investors

Ocular Therapeutix focuses on drug development and treatment for retinal diseases, with an emphasis on wet age-related macular degeneration and expanding into diabetic retinopathy conditions. The company aims to reduce therapeutic burden and improve patient outcomes in retinal care.

4 investors

Oculis is a biopharmaceutical company developing pharmaceutical drug products, with a focus on ophthalmic and eye disease treatments. It conducts formulation, process, and analytical development to advance drug candidates from early research through later development stages.

4 investors

Ohalo develops agricultural products designed to improve farmer productivity and livelihoods globally. The company focuses on solving farming challenges through innovation.

4 investors

Olive develops machine learning and signal processing technology with applications across education, mobility, and healthcare sectors. The company combines expertise in ML, signal processing, and biomedical engineering to deliver field-tested solutions.

4 investors

OMass is a biotech company that originated as a spinout from Oxford University, developing specialized treatments for patient populations with high unmet medical needs. The company builds integrated development and commercialization capabilities while partnering to advance programs addressing large indications.

4 investors

Onava is a drug discovery company that combines AI-native protein engineering, autonomous orchestration of model training and experimental feedback, and high-throughput functional assays to develop next-generation therapeutics. Its platform uses a cross-program data flywheel where insights from each program inform future candidate optimization.

4 investors

Onc.AI develops the Onclara platform, which uses oncology real-world data to build predictive and prognostic AI models for cancer decision-making. Its products serve pharma companies with Phase IB/II clinical trial decisions and predict immunotherapy response and outcomes for metastatic lung cancer patients.

4 investors

Oncko develops machine learning and experimental platforms to discover optimized multi-drug cancer treatment combinations by screening against resistance mechanisms. The company serves oncology drug developers seeking to identify efficacious combination regimens for cancer indications.

4 investors

OncoPrecision develops precision oncology medicines, including antibody-drug conjugates and bispecific antibodies, for blood cancers and hard-to-treat solid tumors. The company uses patient-derived tumor biology and AI-enhanced discovery to identify therapeutic targets and engineering approaches.

4 investors

Clinical-stage immuno-oncology company developing antibodies derived from the immune systems of 'Elite' cancer responders.

4 investors

OnCusp Therapeutics develops oncology therapeutics for cancer treatment, including antibody-drug conjugates and small molecule compounds in clinical and preclinical stages. The company operates as a clinical-stage biopharmaceutical firm advancing multiple programs toward regulatory approval and patient access.

4 investors

OneBio Sciences provides clinical-grade single-cell RNA sequencing analysis of tumor samples to support cancer diagnostics and drug development. The platform delivers tumor intelligence reports with functional signatures for precision oncology within two weeks.

4 investors

One Codex operates a data platform for applied microbial genomics and metagenomics, supporting applications in clinical diagnostics, food safety, and biosecurity. The company was acquired by Invitae in 2021 and spun out as independent in 2022.

4 investors

Ophidion is a biotechnology company developing therapeutics based on the cholinergic system and lynx gene modulators, which regulate nicotinic acetylcholine receptors. Its drug discovery programs target neurological and related conditions, including an early small-molecule smoking cessation candidate and peptide/protein programs.

4 investors

Dowds is a UK-based engineering company providing integrated technical solutions and design-led project delivery for complex built environments, with particular expertise in healthcare infrastructure, mechanical, electrical, and building systems integration.

4 investors

Orasis is a pharmaceutical company developing drugs for the eye, operating in the ophthalmology and eyecare space. It is backed by healthcare-focused investors and announced a Series D financing in October 2024.

4 investors

Orbis Diagnostics is developing a point-of-care diagnostics platform that produces blood test results from a single fingerstick of blood. The product targets clinical blood testing in the medical diagnostics field.

4 investors

Orbit Discovery provides peptide discovery solutions for pharmaceutical and biotechnology companies, serving both large pharmaceutical firms and smaller biotech enterprises.

4 investors